http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 12 Aug 2026 03:06:35 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Downgrades/Berenberg+Downgrades+Novo+Nordisk+%28NVO%29+to+Hold/26907839.html <p>Berenberg analyst Kerry Holford downgraded Novo Nordisk (NYSE: NVO) from Buy to Hold with a price target of $47.00 (from $50.00).</p><p>The analyst comments: “Since the beginning of the year, our Buy thesis on Novo Nordisk has been predicated on upside to Wegovy pill expectations. This has played out through H1. We expect the “Battle of the Pills” to step up a gear in H2. Valuation multiple expansion from here will require confirmation that Novo can retain its lead in obesity orals and grow its position in the injectable market. We await pipeline progress to support this. We downgrade to Hold http://www.streetinsider.com/Downgrades/Berenberg+Downgrades+Novo+Nordisk+%28NVO%29+to+Hold/26907839.html Wed, 12 Aug 2026 03:06:35 -0400 NVO http://www.streetinsider.com/Analyst+Comments/Berenberg+Downgrades+Novo+Nordisk+%28NVO%29+to+Hold/26907839.html <p>Berenberg analyst Kerry Holford downgraded Novo Nordisk (NYSE: NVO) from Buy to Hold with a price target of $47.00 (from $50.00).</p><p>The analyst comments: “Since the beginning of the year, our Buy thesis on Novo Nordisk has been predicated on upside to Wegovy pill expectations. This has played out through H1. We expect the “Battle of the Pills” to step up a gear in H2. Valuation multiple expansion from here will require confirmation that Novo can retain its lead in obesity orals and grow its position in the injectable market. We await pipeline progress to support this. We downgrade to Hold http://www.streetinsider.com/Analyst+Comments/Berenberg+Downgrades+Novo+Nordisk+%28NVO%29+to+Hold/26907839.html Wed, 12 Aug 2026 03:06:35 -0400 NVO http://www.streetinsider.com/Intl+Ratings/Berenberg+Downgrades+Novo+Nordisk+%28NOVOB%3ADC%29+%28NVO%29+to+Hold/26907838.html <p>Berenberg analyst Kerry Holford downgraded Novo Nordisk (NOVOB:DC) (NYSE: NVO) from Buy to Hold with a price target of DKK305.00 (from DKK325.00).</p><p>The analyst comments: “Since the beginning of the year, our Buy thesis on Novo Nordisk has been predicated on upside to Wegovy pill expectations. This has played out through H1. We expect the “Battle of the Pills” to step up a gear in H2. Valuation multiple expansion from here will require confirmation that Novo can retain its lead in obesity orals and grow its position in the injectable market. We await pipeline progress to support this. We downgrade to http://www.streetinsider.com/Intl+Ratings/Berenberg+Downgrades+Novo+Nordisk+%28NOVOB%3ADC%29+%28NVO%29+to+Hold/26907838.html Wed, 12 Aug 2026 03:06:05 -0400 NVO http://www.streetinsider.com/Intl+Ratings/Berenberg+Downgrades+Novo+Nordisk+%28NOVOB%3ADC%29+%28NVO%29+to+Hold/26907838.html <p>Berenberg analyst Kerry Holford downgraded Novo Nordisk (NOVOB:DC) (NYSE: NVO) from Buy to Hold with a price target of DKK305.00 (from DKK325.00).</p><p>The analyst comments: “Since the beginning of the year, our Buy thesis on Novo Nordisk has been predicated on upside to Wegovy pill expectations. This has played out through H1. We expect the “Battle of the Pills” to step up a gear in H2. Valuation multiple expansion from here will require confirmation that Novo can retain its lead in obesity orals and grow its position in the injectable market. We await pipeline progress to support this. We downgrade to http://www.streetinsider.com/Intl+Ratings/Berenberg+Downgrades+Novo+Nordisk+%28NOVOB%3ADC%29+%28NVO%29+to+Hold/26907838.html Wed, 12 Aug 2026 03:06:05 -0400 NVO http://www.streetinsider.com/Downgrades/Berenberg+Downgrades+Novo+Nordisk+%28NOVOB%3ADC%29+%28NVO%29+to+Hold/26907838.html <p>Berenberg analyst Kerry Holford downgraded Novo Nordisk (NOVOB:DC) (NYSE: NVO) from Buy to Hold with a price target of DKK305.00 (from DKK325.00).</p><p>The analyst comments: “Since the beginning of the year, our Buy thesis on Novo Nordisk has been predicated on upside to Wegovy pill expectations. This has played out through H1. We expect the “Battle of the Pills” to step up a gear in H2. Valuation multiple expansion from here will require confirmation that Novo can retain its lead in obesity orals and grow its position in the injectable market. We await pipeline progress to support this. We downgrade to http://www.streetinsider.com/Downgrades/Berenberg+Downgrades+Novo+Nordisk+%28NOVOB%3ADC%29+%28NVO%29+to+Hold/26907838.html Wed, 12 Aug 2026 03:06:05 -0400 NVO http://www.streetinsider.com/Downgrades/Berenberg+Downgrades+Novo+Nordisk+%28NOVOB%3ADC%29+%28NVO%29+to+Hold/26907838.html <p>Berenberg analyst Kerry Holford downgraded Novo Nordisk (NOVOB:DC) (NYSE: NVO) from Buy to Hold with a price target of DKK305.00 (from DKK325.00).</p><p>The analyst comments: “Since the beginning of the year, our Buy thesis on Novo Nordisk has been predicated on upside to Wegovy pill expectations. This has played out through H1. We expect the “Battle of the Pills” to step up a gear in H2. Valuation multiple expansion from here will require confirmation that Novo can retain its lead in obesity orals and grow its position in the injectable market. We await pipeline progress to support this. We downgrade to http://www.streetinsider.com/Downgrades/Berenberg+Downgrades+Novo+Nordisk+%28NOVOB%3ADC%29+%28NVO%29+to+Hold/26907838.html Wed, 12 Aug 2026 03:06:05 -0400 NVO http://www.streetinsider.com/Analyst+Comments/Berenberg+Downgrades+Novo+Nordisk+%28NOVOB%3ADC%29+%28NVO%29+to+Hold/26907838.html <p>Berenberg analyst Kerry Holford downgraded Novo Nordisk (NOVOB:DC) (NYSE: NVO) from Buy to Hold with a price target of DKK305.00 (from DKK325.00).</p><p>The analyst comments: “Since the beginning of the year, our Buy thesis on Novo Nordisk has been predicated on upside to Wegovy pill expectations. This has played out through H1. We expect the “Battle of the Pills” to step up a gear in H2. Valuation multiple expansion from here will require confirmation that Novo can retain its lead in obesity orals and grow its position in the injectable market. We await pipeline progress to support this. We downgrade to http://www.streetinsider.com/Analyst+Comments/Berenberg+Downgrades+Novo+Nordisk+%28NOVOB%3ADC%29+%28NVO%29+to+Hold/26907838.html Wed, 12 Aug 2026 03:06:05 -0400 NVO http://www.streetinsider.com/Analyst+Comments/Berenberg+Downgrades+Novo+Nordisk+%28NOVOB%3ADC%29+%28NVO%29+to+Hold/26907838.html <p>Berenberg analyst Kerry Holford downgraded Novo Nordisk (NOVOB:DC) (NYSE: NVO) from Buy to Hold with a price target of DKK305.00 (from DKK325.00).</p><p>The analyst comments: “Since the beginning of the year, our Buy thesis on Novo Nordisk has been predicated on upside to Wegovy pill expectations. This has played out through H1. We expect the “Battle of the Pills” to step up a gear in H2. Valuation multiple expansion from here will require confirmation that Novo can retain its lead in obesity orals and grow its position in the injectable market. We await pipeline progress to support this. We downgrade to http://www.streetinsider.com/Analyst+Comments/Berenberg+Downgrades+Novo+Nordisk+%28NOVOB%3ADC%29+%28NVO%29+to+Hold/26907838.html Wed, 12 Aug 2026 03:06:05 -0400 NVO http://www.streetinsider.com/Corporate+News/Novo+Nordisk+launches+once-weekly+basal+insulin+Awiqli+nationwide/26902758.html <p>Novo Nordisk (NYSE: NVO) has launched Awiqli (insulin icodec-abae) injection 700 units/mL nationally, following U.S. Food and Drug Administration approval earlier this year. The company describes it as the first once-weekly basal insulin approved to improve glycemic control in adults with type 2 diabetes, used as an adjunct to diet and exercise.</p><p>Awiqli is available at retail pharmacies nationwide, delivered via a prefilled FlexTouch pen. Eligible patients may lower out-of-pocket costs to as little as $35 per month through Novo Nordisk's affordability program.</p><p>The FDA approval was based on results from the ONWARDS phase 3a clinical program, which included three randomized, open-label http://www.streetinsider.com/Corporate+News/Novo+Nordisk+launches+once-weekly+basal+insulin+Awiqli+nationwide/26902758.html Tue, 11 Aug 2026 09:13:10 -0400 NVO http://www.streetinsider.com/Hot+Corp.+News/Novo+Nordisk+launches+once-weekly+basal+insulin+Awiqli+nationwide/26902758.html <p>Novo Nordisk (NYSE: NVO) has launched Awiqli (insulin icodec-abae) injection 700 units/mL nationally, following U.S. Food and Drug Administration approval earlier this year. The company describes it as the first once-weekly basal insulin approved to improve glycemic control in adults with type 2 diabetes, used as an adjunct to diet and exercise.</p><p>Awiqli is available at retail pharmacies nationwide, delivered via a prefilled FlexTouch pen. Eligible patients may lower out-of-pocket costs to as little as $35 per month through Novo Nordisk's affordability program.</p><p>The FDA approval was based on results from the ONWARDS phase 3a clinical program, which included three randomized, open-label http://www.streetinsider.com/Hot+Corp.+News/Novo+Nordisk+launches+once-weekly+basal+insulin+Awiqli+nationwide/26902758.html Tue, 11 Aug 2026 09:13:10 -0400 NVO http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NOVO+NORDISK+A+S++++++++++For%3A+Aug+10/26895966.html si-local-file:///var/storage/secattach/20260810/26895966.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NOVO+NORDISK+A+S++++++++++For%3A+Aug+10/26895966.html Mon, 10 Aug 2026 10:47:00 -0400 NOVOB NVO O.00291573 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NOVO+NORDISK+A+S++++++++++For%3A+Aug+10/26895966.html si-local-file:///var/storage/secattach/20260810/26895966.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NOVO+NORDISK+A+S++++++++++For%3A+Aug+10/26895966.html Mon, 10 Aug 2026 10:47:00 -0400 NOVOB NVO O.00291573 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NOVO+NORDISK+A+S++++++++++For%3A+Aug+10/26895966.html si-local-file:///var/storage/secattach/20260810/26895966.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NOVO+NORDISK+A+S++++++++++For%3A+Aug+10/26895966.html Mon, 10 Aug 2026 10:47:00 -0400 NOVOB NVO O.00291573 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NOVO+NORDISK+A+S++++++++++For%3A+Aug+06/26895946.html si-local-file:///var/storage/secattach/20260810/26895946.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NOVO+NORDISK+A+S++++++++++For%3A+Aug+06/26895946.html Mon, 10 Aug 2026 10:42:00 -0400 NOVOB NVO O.00291573 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NOVO+NORDISK+A+S++++++++++For%3A+Aug+06/26895946.html si-local-file:///var/storage/secattach/20260810/26895946.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NOVO+NORDISK+A+S++++++++++For%3A+Aug+06/26895946.html Mon, 10 Aug 2026 10:42:00 -0400 NOVOB NVO O.00291573 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NOVO+NORDISK+A+S++++++++++For%3A+Aug+06/26895946.html si-local-file:///var/storage/secattach/20260810/26895946.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NOVO+NORDISK+A+S++++++++++For%3A+Aug+06/26895946.html Mon, 10 Aug 2026 10:42:00 -0400 NOVOB NVO O.00291573 http://www.streetinsider.com/Intl+Ratings/Novo+Nordisk+%28NOVOB%3ADC%29+%28NVO%29+PT+Lowered+to+DKK310+at+Citi/26886530.html Citi analyst Graham Parry lowered the price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO) to DKK310.00 (from DKK330.00) while maintaining a Neutral rating. http://www.streetinsider.com/Intl+Ratings/Novo+Nordisk+%28NOVOB%3ADC%29+%28NVO%29+PT+Lowered+to+DKK310+at+Citi/26886530.html Fri, 07 Aug 2026 04:56:22 -0400 NVO http://www.streetinsider.com/Intl+Ratings/Novo+Nordisk+%28NOVOB%3ADC%29+%28NVO%29+PT+Lowered+to+DKK310+at+Citi/26886530.html Citi analyst Graham Parry lowered the price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO) to DKK310.00 (from DKK330.00) while maintaining a Neutral rating. http://www.streetinsider.com/Intl+Ratings/Novo+Nordisk+%28NOVOB%3ADC%29+%28NVO%29+PT+Lowered+to+DKK310+at+Citi/26886530.html Fri, 07 Aug 2026 04:56:22 -0400 NVO http://www.streetinsider.com/Analyst+PT+Change/Novo+Nordisk+%28NOVOB%3ADC%29+%28NVO%29+PT+Lowered+to+DKK310+at+Citi/26886530.html Citi analyst Graham Parry lowered the price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO) to DKK310.00 (from DKK330.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/Novo+Nordisk+%28NOVOB%3ADC%29+%28NVO%29+PT+Lowered+to+DKK310+at+Citi/26886530.html Fri, 07 Aug 2026 04:56:22 -0400 NVO http://www.streetinsider.com/Analyst+PT+Change/Novo+Nordisk+%28NOVOB%3ADC%29+%28NVO%29+PT+Lowered+to+DKK310+at+Citi/26886530.html Citi analyst Graham Parry lowered the price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO) to DKK310.00 (from DKK330.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/Novo+Nordisk+%28NOVOB%3ADC%29+%28NVO%29+PT+Lowered+to+DKK310+at+Citi/26886530.html Fri, 07 Aug 2026 04:56:22 -0400 NVO http://www.streetinsider.com/Analyst+PT+Change/Novo+Nordisk+%28NVO%29+PT+Raised+to+%2447+at+BMO+Capital/26878994.html BMO Capital analyst Evan Seigerman raised the price target on Novo Nordisk (NYSE: NVO) to $47.00 (from $45.00) while maintaining a Market Perform rating. http://www.streetinsider.com/Analyst+PT+Change/Novo+Nordisk+%28NVO%29+PT+Raised+to+%2447+at+BMO+Capital/26878994.html Thu, 06 Aug 2026 07:50:40 -0400 NVO http://www.streetinsider.com/Intl+Ratings/Novo+Nordisk+%28NOVOB%3ADC%29+%28NVO%29+PT+Raised+to+DKK310+at+Barclays/26877045.html Barclays analyst James Gordon raised the price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO) to DKK310.00 (from DKK300.00) while maintaining a Equalweight rating. http://www.streetinsider.com/Intl+Ratings/Novo+Nordisk+%28NOVOB%3ADC%29+%28NVO%29+PT+Raised+to+DKK310+at+Barclays/26877045.html Thu, 06 Aug 2026 04:56:02 -0400 NVO http://www.streetinsider.com/Intl+Ratings/Novo+Nordisk+%28NOVOB%3ADC%29+%28NVO%29+PT+Raised+to+DKK310+at+Barclays/26877045.html Barclays analyst James Gordon raised the price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO) to DKK310.00 (from DKK300.00) while maintaining a Equalweight rating. http://www.streetinsider.com/Intl+Ratings/Novo+Nordisk+%28NOVOB%3ADC%29+%28NVO%29+PT+Raised+to+DKK310+at+Barclays/26877045.html Thu, 06 Aug 2026 04:56:02 -0400 NVO http://www.streetinsider.com/Analyst+PT+Change/Novo+Nordisk+%28NOVOB%3ADC%29+%28NVO%29+PT+Raised+to+DKK310+at+Barclays/26877045.html Barclays analyst James Gordon raised the price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO) to DKK310.00 (from DKK300.00) while maintaining a Equalweight rating. http://www.streetinsider.com/Analyst+PT+Change/Novo+Nordisk+%28NOVOB%3ADC%29+%28NVO%29+PT+Raised+to+DKK310+at+Barclays/26877045.html Thu, 06 Aug 2026 04:56:02 -0400 NVO http://www.streetinsider.com/Analyst+PT+Change/Novo+Nordisk+%28NOVOB%3ADC%29+%28NVO%29+PT+Raised+to+DKK310+at+Barclays/26877045.html Barclays analyst James Gordon raised the price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO) to DKK310.00 (from DKK300.00) while maintaining a Equalweight rating. http://www.streetinsider.com/Analyst+PT+Change/Novo+Nordisk+%28NOVOB%3ADC%29+%28NVO%29+PT+Raised+to+DKK310+at+Barclays/26877045.html Thu, 06 Aug 2026 04:56:02 -0400 NVO